IQVIA’s third-quarter orders and revenue beat expectations, but acquisitions drove the increase in full-year guidance
Research & Development Solutions drove IQVIA’s third-quarter earnings beat, while order momentum also supported improving demand. At the same time, the backlog cleanup was larger than expected, and full-year organic growth guidance was trimmed slightly.
Original source：J.P. MorganFirst published on Unhidea：Original source date：
Key takeaway
J.P. Morgan believes demand for IQVIA’s clinical research services and order momentum are improving, but the increase in full-year revenue guidance relies on acquisitions, and the backlog cleanup has also raised questions about the quality of growth.
What drove the third-quarter beat?
IQVIA’s third-quarter revenue was 4.428 billion dollars, up 8.0% year over year, above the market expectation of 4.366 billion dollars and the upper end of company guidance. The main contribution came from Research & Development Solutions (R&DS), whose revenue was 2.639 billion dollars, above the market expectation of 2.577 billion dollars.
Commercial Solutions revenue was 1.789 billion dollars, up 6.9% year over year and broadly in line with market expectations. Adjusted EBITDA was 1.032 billion dollars, above the market expectation of 1.015 billion dollars; free cash flow was 667 million dollars, also above the market expectation of 542 million dollars.
Why does order growth support improving demand?
R&DS had a third-quarter book-to-bill ratio of 1.2, above the market expectation of 1.17 and broadly in line with buy-side expectations as assessed by J.P. Morgan from its conversations. Net new orders over the past 12 months were 11.7 billion dollars, up 14% year over year, marking five consecutive quarters of growth.
At the end of the third quarter, the amount of contracted backlog expected to convert into revenue over the following 12 months was 9.4 billion dollars, up 10% year over year. Management also said emerging biotech companies had raised approximately 90 billion dollars year to date, up more than 85% year over year; clinical trial starts and customer request-for-proposal activity also continued to grow rapidly.
Full-service orders from large pharmaceutical companies increased year over year. Strategic partnerships rebid over the past two years have begun to produce higher win rates and more bidding opportunities, providing another source of order growth.
What does the 2.1 billion-dollar backlog cleanup mean?
The company removed approximately 2.1 billion dollars from its backlog, about 6% of the 32.6 billion-dollar backlog balance and more than management’s previous estimate of approximately 5%. The cleanup mainly involved trials that had made no progress for more than 18 months and were not expected to restart in the near term.
Management said the cleanup does not affect historical financial results, 2026 guidance, net new orders, the book-to-bill ratio or revenue expected to convert over the next 12 months; cancellation rates remain within the historical normal range. J.P. Morgan believes this information helps ease investor concerns about a broader deterioration in trial activity.
If the removed trials restart, their value will be added back to the backlog, but will not count toward future net new orders or the book-to-bill ratio, avoiding counting old projects as new orders again.
Why the reservations despite higher full-year guidance?
The company raised its 2026 revenue guidance from 17.275 billion–17.475 billion dollars to 17.35 billion–17.5 billion dollars, but the entire increase came from a higher contribution from acquisitions. At constant exchange rates, the midpoint of guidance implies organic growth of approximately 4.2%, down from approximately 4.3% previously.
Based on results for the first three quarters, implied fourth-quarter revenue guidance is 4.403 billion–4.553 billion dollars. Management attributed the implied slowdown in growth to a higher comparison base in the prior-year period and expects exchange rates to be a headwind of approximately 70 basis points to fourth-quarter revenue.
How do margins and AI progress affect the institutional view?
The third-quarter adjusted EBITDA margin rose approximately 20 basis points year over year to 23.3%. Pass-through costs and exchange rates together created a non-operating headwind of approximately 60 basis points. According to J.P. Morgan’s follow-up inquiries, scale benefits from business volume and productivity initiatives, including AI, drove operating improvement, partly offset by a headwind from business mix.
The company said it has deployed 415 AI agents and cited an AI solution for country and trial-site modeling that shortened a phase-three autoimmune disease project by nine months. J.P. Morgan believes customer wins and productivity examples make the discussion of AI’s contribution more concrete.
J.P. Morgan maintained its overweight rating and raised its December 2027 price target from 295 dollars to 325 dollars. The company plans to present its overall framework for 2027 at its investor day on 1 December 2026; formal annual guidance is expected alongside full-year results in February 2027.
